I spent 15 years as the FDA’s “biotechnology czar” at a time when many of the biopharmaceutical companies were small startups needing guidance as they negotiated the regulatory maze.
Research and breakthroughs at the intersection of biology and medicine — from gene editing and synthetic biology to clinical trials, diagnostics, and the science driving next-generation therapies.
